Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.49 |
| ▸ | DRD2 | P14416 | 11/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3581618 | 0.99 | DRD3 (0.49) | DRD3KCNH2DRD2CYP1A2MGLL | |
| SCHEMBL10107827 | 0.78 | DRD3 (0.57) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL3570811 | 0.77 | DRD3 (0.49) | DRD3KCNH2DRD2CYP1A2 | |
| Hydrochloric Acid SCHEMBL3560825 | 0.76 | DRD3 (0.48) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL378256 | 0.76 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL13089084 | 0.76 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL14606013 | 0.76 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL919354 | 0.76 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL6003533 | 0.75 | DRD3 (0.54) | DRD3KCNH2DRD2CYP1A2 | |
| SCHEMBL13007625 | 0.75 | DRD3 (0.55) | DRD3KCNH2DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | claimed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | claimed |
| EP-2007751-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | claimed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | claimed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| EP-2007751-B1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222266-B2 | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-18 | — | — | US | disclosed |
| EP-2007751-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113260-A1 | AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069416-A1 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, HTR3A | DRD3 1/4885KCNH2 1920/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.